Lee Meng-Rui, Sheng Wang-Huei, Hung Chien-Ching, Yu Chong-Jen, Lee Li-Na, Hsueh Po-Ren
Emerg Infect Dis. 2015 Sep;21(9):1638-46. doi: 10.3201/2109.141634.
Mycobacterium abscessus complex comprises a group of rapidly growing, multidrug-resistant, nontuberculous mycobacteria that are responsible for a wide spectrum of skin and soft tissue diseases, central nervous system infections, bacteremia, and ocular and other infections. M. abscessus complex is differentiated into 3 subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. The 2 major subspecies, M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, have different erm(41) gene patterns. This gene provides intrinsic resistance to macrolides, so the different patterns lead to different treatment outcomes. M. abscessus complex outbreaks associated with cosmetic procedures and nosocomial transmissions are not uncommon. Clarithromycin, amikacin, and cefoxitin are the current antimicrobial drugs of choice for treatment. However, new treatment regimens are urgently needed, as are rapid and inexpensive identification methods and measures to contain nosocomial transmission and outbreaks.
脓肿分枝杆菌复合体是一组生长迅速、耐多药的非结核分枝杆菌,可导致多种皮肤和软组织疾病、中枢神经系统感染、菌血症以及眼部和其他感染。脓肿分枝杆菌复合体分为3个亚种:脓肿分枝杆菌脓肿亚种、脓肿分枝杆菌马西利亚亚种和脓肿分枝杆菌博列蒂亚种。两个主要亚种,即脓肿分枝杆菌脓肿亚种和脓肿分枝杆菌马西利亚亚种,具有不同的erm(41)基因模式。该基因赋予对大环内酯类药物的固有耐药性,因此不同的模式导致不同的治疗结果。与美容手术和医院内传播相关的脓肿分枝杆菌复合体暴发并不罕见。克拉霉素、阿米卡星和头孢西丁是目前治疗的抗菌药物选择。然而,迫切需要新的治疗方案,以及快速且廉价的鉴定方法和控制医院内传播及暴发的措施。